This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study sample
The sample size was calculated on the basis that the frequency of an unfavourable outcome was the same in both groups, in this case 10%. Using this value, a maximum acceptable difference between the groups of 15%, a Type I error of 0.05 and a power of 0.90, it was decided that 69 patients were needed in both groups. A total of 390 episodes of FN occurred in 313 children. Of these, 168 episodes were initially classified as low risk for IBI. After hospitalisation for 24 to 36 hours, 7 episodes were reclassified as high risk and were excluded from the study. Of the 161 episodes definitively classified as low risk for IBI, 12 were excluded because of lack of informed consent, rural origin, lack of notification, or medical reasons. In the end, 149 low-risk febrile episodes occurring in 107 patients were randomly allocated to either the ambulatory group (n=78) or the hospital-based group (n=71). The mean age was 55 years (95% confidence interval, CI: 45 -66) in the ambulatory group and 66 years (95% CI: 57 -74) in the hospital-based group. There were 43% males in the ambulatory group and 49% in the hospital-based group.
Study design
This was a multi-centre randomised controlled trial (RCT). Children from six hospitals were randomly assigned to either ambulatory or hospital-based treatment. The method of randomisation was not reported and the study was unblinded. The patients were followed up until the fever resolved and the absolute neutrophil count reached 500/microL.
Analysis of effectiveness
The analysis was conducted on an intention to treat basis. The primary health outcome used was the proportion of favourable outcomes (i.e. no indication of IBI was present and the child completed follow-up without requiring antimicrobial adjustments or readmission). An unfavourable outcome was defined as one or more of the following: haemodynamic instability not attributable to volume loss; axillary temperature more than 38 degrees C after day 4; increase in temperature for at least 24 hours after a 48-hour afebrile period;
an ascending serum C-reactive protein (CRP) curve or a non descending curve over normal limits after day 3 persisting for at least 2 consecutive days; isolation of a bacterial pathogen from a significant sample on day 3; or death resulting from a febrile episode, attributable to infection.
The groups were shown to be comparable at baseline.
Effectiveness results
Seventy-four (95%) of the ambulatory group and 67 (94%) of the hospital-based group had a favourable outcome. The difference was described as not statistically significant but the p-value was not given.
There were 11 unfavourable outcomes in 8 patients (4 in each treatment group). Seven of these patients eventually recovered after their therapy was changed, but a 1-year old child (with a Stage III neuroblastoma) who had initially been allocated to the hospital-based group died.
Clinical conclusions
When children with FN were classified as low risk of IBI, the chance of a favourable outcome was no different whether they were treated in a hospital setting or given ambulatory treatment.
